Fig. 2.

CD4⁺CD25⁺FoxP3⁺ regulatory T cells are reduced after administration of an anti-CD25 mAb. Uninfected male rats were administered 2 mg of anti-CD25 mAb (NDS-63) per rat or administered vehicle alone on days −1, 1, 10, and 20 during the experiment, and at days 7 and 30, cells from lungs, spleen, and lymph nodes were collected from rats and stained with FITC–anti-CD4, phycoerythrin–anti-CD25, and allophycocyanin–anti-FoxP3. Viable cells were gated on lymphocytes and are expressed as the percentage of lymphocytes that are CD4⁺CD25⁺FoxP3⁺. The vertical bars indicate means ± SEM, and a significant reduction in proportion of cells is indicated (*, P < 0.05). Representative FACS analyses of spleens from rats treated with vehicle alone (left) or anti-CD25 mAb (right) for 30 days are shown as a density dot plot of CD4⁺CD25⁺ viable lymphocytes; of the CD4⁺CD25⁺ lymphocytes, ≈90% are FoxP3⁺ for both treatment groups.